Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for painCo-Development and Licensing Agreement • June 2nd, 2021
This letter sets forth the understanding between POZEN INC. (“POZEN”) and Astrazeneca AB (“Astrazeneca”) with regard to the matters set forth below and in connection with the Collaboration Agreement. Any capitalized terms not otherwise defined herein shall have the meaning given such term in the Collaboration Agreement. POZEN and Astrazeneca herein are collectively referred to as the Parties.
Amendment to co-development and licensing agreement for naproxen and esomeprazole combination for painCo-Development and Licensing Agreement • September 28th, 2021
Musculoskeletal » Arthritis » Osteoarthritis Musculoskeletal » Arthritis » Rheumatoid arthritis Musculoskeletal » Symptoms » Bone pain Musculoskeletal » Symptoms » Muscular pain Drug delivery
Second amendment to co-development and licensing agreement for naproxen and esomeprazole combination for painCo-Development and Licensing Agreement • March 12th, 2021
This Amendment No. 2 to the Collaboration and License Agreement (this “Amendment No. 2”) is made effective as of October 1, 2008 (the “Amendment No. 2 Effective Date”) by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“AstraZeneca”). POZEN and AstraZeneca may be referred to herein individually as a “Party,” or collectively as the “Parties.”
First amendment to co-development and licensing agreement for naproxen and esomeprazole combination for painCo-Development and Licensing Agreement • March 13th, 2021
This Amendment No. 1 to the Collaboration and License Agreement (this “Amendment”) is made effective as of September 6, 2007 (the “Amendment Effective Date”) by and between POZEN INC., a Delaware corporation having offices at 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina (“POZEN”), and ASTRAZENECA AB, a Swedish corporation having an office at SE-431 83, Mölndal, Sweden (“AstraZeneca”).
Co-development and licensing agreement for coated vascular injection cathetersCo-Development and Licensing Agreement • August 16th, 2024
Bactiguard and Smartwise Sweden have entered into a joint development project for advanced, Bactiguard-coated vascular injection catheters. At the same time, a license agreement has been signed.
Term Sheet: [****] Co-development and Licensing AgreementCo-Development and Licensing Agreement • May 14th, 2010 • IntelGenx Technologies Corp. • Pharmaceutical preparations
The purpose of this term sheet (“Term Sheet”) is to set forth the terms for an exclusive worldwide co- development and licensing agreement between IntelGenx Technologies Corp., a US corporation, or any subsidiaries thereof (“IGXT”) and RedHill Biopharma Ltd. (“RedHill”), an Israeli corporation or its designee (collectively the “Parties”). This Term Sheet is legally binding on the Parties and is subject only to satisfactory customary due diligence by RedHill, verifying inter alia that no drastic changes emerge vis a vis the currently estimated budgetary requirements, and regulatory, technical, IP and market risks, and the Parties entering into definite documentation (the “Agreement”) elaborating on the terms of this Term Sheet, and other customary terms including, without limitation, representations and warranties, liability and indemnity, and including a side letter to be executed by the original inventors/licensors (if other than IGXT).
TERMS FOR A CO-DEVELOPMENT AND LICENSING AGREEMENT WHEREAS WinWin Pharmaceuticals Canada ("WinWin") to 136 Northview, Dollard, Quebec, Canada and Bioenvision, Inc. ("Bioenvision") of Trafalgar House, 11 Waterloo Place, St. James's, London SW1Y 4AU...Co-Development and Licensing Agreement • October 13th, 1999 • Bioenvision Inc • Non-operating establishments
